Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.
Oncology (Williston Park)
; 31(9): 659-67, 2017 09 15.
Article
em En
| MEDLINE
| ID: mdl-29071693
ABSTRACT
Until recently, therapeutic strategies for melanoma brain metastases focused on local treatments surgery, whole-brain radiation therapy, and stereotactic radiosurgery. Historically, systemic therapy had limited utility. Immunotherapeutic drugs, such as anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 agents, and agents targeting the BRAF-MEK pathway have revolutionized the systemic treatment of melanoma brain metastases. Recent clinical trials of these agents have shown activity against melanoma brain metastases, and they are increasingly being used in clinical practice. In this article, we provide an overview of the currently available systemic agents, including immunotherapeutic agents and targeted tyrosine kinase inhibitors. We also provide a practical management algorithm to guide the practicing oncologist in the use of both of these new therapies and the more traditional local treatments.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Imunossupressores
/
Melanoma
/
Metástase Neoplásica
/
Antineoplásicos
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article